...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: Re: New Apabetalone Clinical Trial for Pulmonary Arterial Hypertension

Nice to see medical trials now finally being conducted in Canada.

Any particular reason why a 16-week trial takes approx 1 1/2 years to complete? (Begins Nov 2018 and ends mid-2020)

Seeing that the 3 trials (Fabry, Renal, PAH, and what follows) all are with Apabetalone, so does this mean that Shenzhen hepalink gets to benefit in all going forward with no additional cash outlay?  

 

Koo

Share
New Message
Please login to post a reply